Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication

医学 利福平 内科学 尿素呼气试验 胃肠病学 奥美拉唑 幽门螺杆菌 人口 克拉霉素 呼吸试验 不利影响 甲硝唑 阿莫西林 抗生素 微生物学 幽门螺杆菌感染 环境卫生 生物
作者
David Y. Graham,Yamil Canaan,James W. Maher,Gregory Wiener,Kristina G. Hultén,Ira N. Kalfus
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:172 (12): 795-802 被引量:72
标识
DOI:10.7326/m19-3734
摘要

Although consensus supports eradication of Helicobacter pylori infections, antimicrobial resistance has substantially reduced eradication rates with most current therapies.To assess the effectiveness of a novel rifabutin-based therapy (RHB-105) for H pylori eradication.Phase 3, double-blind trial (ERADICATE Hp2). (ClinicalTrials.gov: NCT03198507).55 clinical research sites in the United States.455 treatment-naive adults with epigastric discomfort and confirmed H pylori infection.RHB-105 (amoxicillin, 3 g; omeprazole, 120 mg; and rifabutin, 150 mg) versus active comparator (amoxicillin, 3 g, and omeprazole, 120 mg), given as 4 capsules every 8 hours for 14 days.Between-group difference for H pylori eradication rate, demonstrated by 13C urea breath test 4 weeks after treatment, analyzed by using the χ2 test.In the intention-to-treat population, the eradication rate was higher with RHB-105 than with the active comparator (228 vs. 227 patients, respectively; 83.8% [95% CI, 78.4% to 88.0%] vs. 57.7% [95% CI, 51.2% to 64.0%]; P < 0.001). Eradication rates were unaffected by resistance to clarithromycin or metronidazole. No rifabutin resistance was detected. The most commonly reported adverse events (incidence ≥5%) were diarrhea (10.1% with RHB-105 vs. 7.9% with active comparator), headache (7.5% vs. 7.0%), and nausea (4.8% vs. 5.3%).Persons of Asian descent were excluded because of their higher prevalence of poor cytochrome P450 2C19 metabolizers.These findings suggest potential for RHB-105 as first-line empirical H pylori therapy, addressing an unmet need in the current environment of increasing antibiotic resistance.RedHill Biopharma Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
淡定草丛完成签到 ,获得积分10
1秒前
1秒前
2秒前
HEAUBOOK举报SAD求助涉嫌违规
2秒前
YanK发布了新的文献求助10
3秒前
3秒前
3秒前
poorzz发布了新的文献求助10
3秒前
Owen应助peekaboo采纳,获得10
4秒前
yiyiyini完成签到,获得积分10
4秒前
科目三应助只是虚瘦采纳,获得10
4秒前
白日梦发布了新的文献求助10
5秒前
水何澹澹完成签到,获得积分0
5秒前
玛卡巴卡完成签到,获得积分10
5秒前
6秒前
丫丫发布了新的文献求助10
6秒前
xiongyong发布了新的文献求助10
7秒前
7秒前
简单的依珊完成签到,获得积分10
7秒前
qwh完成签到,获得积分20
8秒前
隐形曼青应助哪吒采纳,获得20
9秒前
10秒前
poorzz完成签到,获得积分10
10秒前
run发布了新的文献求助10
11秒前
zsl发布了新的文献求助10
11秒前
万能图书馆应助YanK采纳,获得10
12秒前
白之玉发布了新的文献求助10
13秒前
李伟发布了新的文献求助10
13秒前
Jasper应助丫丫采纳,获得20
16秒前
科研通AI5应助李千澈采纳,获得30
17秒前
安恋雨完成签到 ,获得积分10
18秒前
xiongyong完成签到,获得积分10
18秒前
细腻沛萍发布了新的文献求助10
19秒前
万能图书馆应助白之玉采纳,获得10
22秒前
陈成应助氢氧化钠Li采纳,获得20
22秒前
YanK完成签到,获得积分20
23秒前
飒飒完成签到,获得积分10
24秒前
kk2024完成签到,获得积分10
25秒前
CipherSage应助AlexanderChen采纳,获得10
25秒前
高分求助中
Mass producing individuality 600
Разработка метода ускоренного контроля качества электрохромных устройств 500
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 500
Arthur Ewert: A Life for the Comintern 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi // Kurt Werner Radtke 500
Two Years in Peking 1965-1966: Book 1: Living and Teaching in Mao's China // Reginald Hunt 500
A Combined Chronic Toxicity and Carcinogenicity Study of ε-Polylysine in the Rat 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3824207
求助须知:如何正确求助?哪些是违规求助? 3366533
关于积分的说明 10441059
捐赠科研通 3085772
什么是DOI,文献DOI怎么找? 1697543
邀请新用户注册赠送积分活动 816398
科研通“疑难数据库(出版商)”最低求助积分说明 769611